U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H27N3O5S
Molecular Weight 421.51
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of UTIBAPRILAT

SMILES

C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2N=C(S[C@H]2C(O)=O)C(C)(C)C

InChI

InChIKey=APWZQGVRPRWXQK-NOLJZWGESA-N
InChI=1S/C20H27N3O5S/c1-12(21-14(17(25)26)11-10-13-8-6-5-7-9-13)15(24)23-16(18(27)28)29-19(22-23)20(2,3)4/h5-9,12,14,16,21H,10-11H2,1-4H3,(H,25,26)(H,27,28)/t12-,14-,16-/m0/s1

HIDE SMILES / InChI

Molecular Formula C20H27N3O5S
Molecular Weight 421.51
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Utibapril (FPL 63547) is an ester prodrug of a novel thiadiazoline ACE inhibitor. Utibapril was undergoing phase II clinical studies in the United Kingdom for the treatment of heart failure and hypertension. Utibapril is an angiotensin-converting enzyme (ACE) inhibitor with a proposed tissue-specific inhibitory profile. This implies that at a certain dose, utibapril should be able to inhibit tissue ACE activity without affecting plasma ACE.

Approval Year

PubMed

PubMed

TitleDatePubMed
Cardiac and aortic effects of angiotensin converting enzyme inhibitors.
1991-10
Pharmacological properties of FPL 63547, a novel inhibitor of angiotensin-converting enzyme.
1990-05

Sample Use Guides

Normal Wistar rats were randomly allocated to oral treatment with different doses of utibapril (0, 2, 10, 50, or 250 ug/kg/day) for 30 days. Utibapril significantly inhibited plasma, renal, and vascular ACE but not ventricular ACE activity. Notably, however, only treatment with the highest dose of utibapril resulted in a significant inhibition of plasma ACE, whereas vascular ACE activity was already significantly inhibited after treatment with a lower dose of utibapril.
Route of Administration: Oral
In Vitro Use Guide
Utibapril (FPL 63547), in its active diacid form, was a potent inhibitor of rabbit lung angiotension converting enzyme (ACE) in vitro (IC50 0.51 nM).
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:59:33 GMT 2025
Edited
by admin
on Mon Mar 31 17:59:33 GMT 2025
Record UNII
KN82541NHV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
UTIBAPRILAT
INN   WHO-DD  
INN  
Official Name English
Utibaprilat [WHO-DD]
Preferred Name English
utibaprilat [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C247
Created by admin on Mon Mar 31 17:59:33 GMT 2025 , Edited by admin on Mon Mar 31 17:59:33 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL342372
Created by admin on Mon Mar 31 17:59:33 GMT 2025 , Edited by admin on Mon Mar 31 17:59:33 GMT 2025
PRIMARY
NCI_THESAURUS
C72914
Created by admin on Mon Mar 31 17:59:33 GMT 2025 , Edited by admin on Mon Mar 31 17:59:33 GMT 2025
PRIMARY
INN
6810
Created by admin on Mon Mar 31 17:59:33 GMT 2025 , Edited by admin on Mon Mar 31 17:59:33 GMT 2025
PRIMARY
FDA UNII
KN82541NHV
Created by admin on Mon Mar 31 17:59:33 GMT 2025 , Edited by admin on Mon Mar 31 17:59:33 GMT 2025
PRIMARY
SMS_ID
100000079120
Created by admin on Mon Mar 31 17:59:33 GMT 2025 , Edited by admin on Mon Mar 31 17:59:33 GMT 2025
PRIMARY
EVMPD
SUB00001MIG
Created by admin on Mon Mar 31 17:59:33 GMT 2025 , Edited by admin on Mon Mar 31 17:59:33 GMT 2025
PRIMARY
EPA CompTox
DTXSID10149015
Created by admin on Mon Mar 31 17:59:33 GMT 2025 , Edited by admin on Mon Mar 31 17:59:33 GMT 2025
PRIMARY
CAS
109683-79-6
Created by admin on Mon Mar 31 17:59:33 GMT 2025 , Edited by admin on Mon Mar 31 17:59:33 GMT 2025
PRIMARY
PUBCHEM
5748833
Created by admin on Mon Mar 31 17:59:33 GMT 2025 , Edited by admin on Mon Mar 31 17:59:33 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY